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Purpose: To report two novel mutation of the tumor-associated calcium signal transducer 2 (TACSTD2) gene in 3 Japanese
patients with gelatinous drop-like corneal dystrophy (GDLD).
Methods: Genomic DNAs were extracted from the peripheral blood of 3 Japanese families. The coding region of
TACSTD2 was amplified by polymerase chain reaction (PCR) and subjected to direct sequencing analysis. Plasmid vectors
harboring normal and mutated TACSTD2 were transfected to the immortalized human corneal epithelial cells to identify
the subcellular localization of the normal and mutated TACSTD2 gene products.
Results:  Sequencing  analysis  of  TACSTD2  revealed  two  novel  homozygous  mutations  (c.
840_841insTCATCATCGCCGGCCTCATC and c.675C>A which may result in frameshift (p.Ile281SerfsX23) and
nonsense (p.Tyr225X) mutations, respectively) in the 3 GDLD patients. Protein expression analysis showed that the
mutated gene product was distributed diffusely in the cytoplasm, whereas the normal gene product accumulated at the
cell-to-cell borders.
Conclusions: This study reports two novel mutations in 3 GDLD families and expands the spectrum of mutations in
TACSTD2 that may cause pathological corneal amyloidosis.
Gelatinous drop-like corneal dystrophy (GDLD; OMIM
204870)  was  first  described  by  Nakaizumi  [1]  as  an
uncommon,  autosomal  recessive  disease,  characterized  by
bilateral corneal amyloidosis. To date, this disease is still quite
rare in many countries, however, it is relatively common in
Japan with a prevalence rate of 1 in 31,546 individuals as
estimated from the frequency of parental consanguinity [2,3].
In the first decade of the lives of GDLD patients, grayish,
subepithelial nodular amyloid depositions appear and result
in severe photophobia, lacrimation, and an ocular foreign
body  sensation  [4,5].  As  the  patients  age,  the  amyloid
depositions typically enlarge, increase in number, coalesce,
and exhibit a mulberry-like appearance, thus leading to severe
bilateral vision loss usually beginning within the third decade
of the patients’ lives.
Tsujikawa et al. [6] revealed through the use of a linkage
analysis and consecutive candidate gene approach that the
specific gene responsible for this disease is tumor-associated
calcium  signal  transducer  2  (TACSTD2).  To  date,  fifteen
reports  have  demonstrated  twenty-three  different  GDLD-
Correspondence to: Satoshi Kawasaki, M.D., Ph.D., Department of
Ophthalmology,  Kyoto  Prefectural  University  of  Medicine,  465
Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto
602-0841,  Japan;  Phone:  +81-75-251-5578;  FAX:
+81-75-251-5663; email: bluenova@koto.kpu-m.ac.jp
causing alterations in TACSTD2 comprised of nine missense-,
five  nonsense-,  and  nine  frameshift-causing  (deletion  and
insertion) mutations from nine different geographical regions
including Japan, China, India, Iran, Tunisia, Estonia, Turkey,
Vietnam, and Europe, most of which used to be developing
regions with a predominance of consanguineous marriage
[6-15]. In the present study, we report two novel TACSTD2
mutations from 3 Japanese GDLD patients.
METHODS
Ethical issues: All experimental procedures were approved by
the Institutional Review Board for Human Studies at Kyoto
Prefectural  University  of  Medicine,  Kyoto,  Japan.  Prior
informed  consent  was  obtained  from  all  patients  after  a
detailed explanation of the study protocols, and this study was
performed in accordance with the tenets of the Declaration of
Helsinki for research involving human subjects.
Subjects:  All  patients  were  given  a  complete  ophthalmic
examination  including  visual  acuity  testing,  noncontact
tonometry,  and  slit-lamp  examination.  For  all  3  GDLD
patients  enrolled  in  this  study,  clinical  diagnosis  was
confirmed  based  upon  slit-lamp  examination  and  the
agreement of at least 2 corneal specialists in our department.
Sequencing  analysis:  Genomic  DNA  was  extracted  from
peripheral  blood  using  a  commercially  available  column-
based DNA extraction kit (DNeasy® Blood & Tissue Kit;
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965QIAGEN  GmbH,  Hilden,  Germany).  Sequencing  analysis
was performed using a commercially available kit (BigDye
3.1; Applied Biosystems, Inc., Foster City, CA). Polymerase
chain reaction (PCR) was performed with a primer pair against
TACSTD2 (M1S1-F-2; 5′-CCT GCA GAC CAT CCC AGA
C-3′, M1S1-R-2; 5′-CAG GAA GCG TGA CTC ACT TG-3′)
which fully covered the coding sequence of this gene. The
PCR  product  was  bi-directionally  sequenced  in  a  20-μl
reaction buffer containing a 2× sequencing mixture and either
of the above primers. After ethanol precipitation, the sequence
products  were  electrophoresed  on  an  automated  capillary
sequencer (Genetic Analyzer 3130xl; Applied Biosystems).
Validation of the sequencing data: As for the family members
related to Case 1 and Case 2, sequencing data was validated
by PCR using a primer pair (M1S1–20ins-F; 5′-TGA AGC
GCC TCA CCG CCG GC-3′, M1S1–20ins-R; 5′-CGA CGA
GGG CCA CCA CGA CC-3′) which encompass the site of
the identified insertional mutation.
As for Case 3, sequencing data was validated by the
single-base  primer  extension  assay  with  a  commercially
available  kit  (SNaPshot®  Multiplex  System;  Applied
Biosystems) with a primer (SS-M1S1-Y225X: 5′-ATC GGC
GAT GCC GCC TAC TA-3′).
Plasmid construction: For the protein expression of either the
wild-type or mutated TACSTD2, DNA fragments covering an
entire open reading frame with or without particular mutations
were amplified by PCR, ligated into an expression vector
pcDNA3.1/V5-His-TOPO (Invitrogen Corp., Carlsbad, CA),
and transformed into chemically competent cells (JM109;
TOYOBO Co., Ltd., Osaka, Japan). A single colony, which
was confirmed via sequencing analysis to have the proper
expected sequence without any unexpected mutations, was
isolated, propagated, and subjected to the plasmid extraction
using  a  commercially  available  column-based  kit
(NucleoBond; MACHEREY-NAGEL GmbH & Co., Düren,
Germany).
Cell culture and gene transfer: SV40 immortalized human
corneal epithelial (HCE-T) cells [16] were subcultured every
4 days and maintained in DMEM/F12 containing 200 U/ml
penicillin and streptomycin, 10% fetal bovine serum (FBS;
Cellgro; Mediatech, Inc., Herndon, VA), 0.1 μg/ml cholera
toxin (List Biologic Laboratories, Inc., Campbell, CA), 5 μg/
ml insulin (Sigma-Aldrich Corp., St. Louis, MO), and 10 ng/
ml human epidermal growth factor (Invitrogen). After the
cells had reached to 70%–80% confluency on a commercially
available  culture-glass  slide  (Nunc  Lab-Tek™  Chamber
Slide™ System; Thermo Fisher Scientific, Inc., Rochester,
NY), each of the plasmids was transfected into the HCE-T
cells using Lipofectamine™ LTX (Invitrogen) according to
the manufacturer’s instructions.
Immunocytostaining analysis: Cells grown on the culture-
glass slide were fixed with Zamboni’s fixative, blocked with
1% skim milk, and then incubated overnight with a primary
antibody at 4 °C. The primary antibody included anti-V5 (MM
IgG1, clone V5005; NACALAI TESQUE, Inc., Kyoto, Japan)
and  normal  mouse  IgG1  (Dako  Denmark  A/S,  Glostrup,
Denmark) as a negative control. After being washed with 0.01
M  of  phosphate  buffered  saline  (PBS),  the  samples  were
incubated  with  a  secondary  antibody  (Alexa  Fluor®  488-
labeled  anti-mouse  or  anti-goat  IgG;  Invitrogen)  at  room
temperature for 1 h. After being washed again with 0.01 M
PBS,  the  sections  or  the  cells  were  counter-stained  with
propidium  iodide,  mounted,  covered  with  coverslips,  and
observed and photographed using a fluorescence microscope
(AX70 TRF; Olympus Corporation, Tokyo, Japan).
RESULTS
Clinical findings: Case 1 involved a 30-year-old Japanese
man  (proband  A)  who  had  undergone  photorefractive
keratectomy (PTK) in his right eye at the age of 16 and in his
left eye at the age of 21. His parents were second cousins to
one-another. He had bilateral diffuse corneal opacities with
multiple  grayish-white  nodular  elevations  located  at  the
subepithelial region (Figure 1A) which fit the classification of
typical mulberry GDLD [17].
Case 2 involved a 29-year-old Japanese female (proband
B) who had undergone PTK in her left eye at the age of 23
and in her right eye at the age of 26. Her parents were first
Figure 1. Images demonstrating the corneas of 3 unrelated GDLD patients. Proband A (A) and proband B (B) demonstrated mulberry-type
GDLD corneas with multiple grayish subepithelial amyloid depositions. Proband C (C) demonstrated a kumquat-like GDLD cornea with
neovascularization.
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966cousins  to  one-another.  Slit-lamp  examination  revealed
grayish amyloid depositions in the bilateral corneas which fit
the classification of typical mulberry GDLD (Figure 1B).
Case  3  involved  an  83-year-old  Japanese  woman
(proband C). Her parents’ marriage was not consanguineous.
She  had  undergone  lamellar  keratoplasty  along  with
keratoepithelioplasty  in  her  left  eye  at  the  age  of  72  and
penetrating keratoplasty in her right eye at the age of 82. Slit-
lamp examination revealed the characteristic findings of a
kumquat-like GDLD subtype with neovascularization in both
of her eyes (Figure 1C). Recurrence of amyloid deposition
was observed in both of her eyes. Surface keratectomy was
performed for her left eye to remove the superficial amyloid
depositions, but no surgical intervention was undertaken for
her right eye because she was too elderly to undergo the
operation at that time.
All surgeries for the 3 cases were performed to treat their
GDLD  corneas.  After  the  surgeries,  case  1  and  case  2
continued to wear soft contact lenses and no recurrence was
observed in the eyes of those patients, however, case 3 was
unable to wear soft contact lenses and recurrence occurred in
both of her eyes. Those findings are in good agreement with
the previous study that reported the protective effect of using
a soft contact lens for the postoperative GDLD cornea [18].
Mutation  analysis:  Sequencing  analysis  of  TACSTD2
revealed a homozygous, 20-base insertion mutation between
the  840th  and  the  841st  nucleotide  positions  (c.
840_841insTCATCATCGCCGGCCTCATC) for proband A
and proband B (Figure 2C), resulting in a putative frameshift
and a premature termination at the 303th amino acid position
(p.Ile281SerfsX23). The respective parents of the proband A
and proband B, as well as the younger sister of proband B, all
of whom had no abnormal findings in their corneas, had one
allele with a mutated TACSTD2 gene and one allele with a
wild-type TACSTD2 gene (Figure 2E), indicating that the
phenotype  well  co-segregates  with  the  genotype  in  these
pedigrees.  Proband  C  was  found  to  have  a  homozygous
substitutive mutation from C to A at the 675th nucleotide
position (c.675C>A), which may result in nonsense mutation
at the 225th amino acid position (p.Tyr225X; Figure 2D). The
sequence data were further validated by the difference in the
length of the PCR products for proband A, proband B, and
their respective family members or by the single-base primer
extension analysis for proband C (Figure 2). Data for other
family members related to proband C were not obtained due
to the fact they refused permission to be enrolled in this study.
Subcellular  localization  of  TACSTD2  protein:  The  V5-
epitope tagged expression plasmid vector harboring either
wild-type or mutated TACSTD2 protein was transfected into
the HCE-T cells. Immunocytological staining analysis using
anti-V5 antibody against the transfected HCE-T cells revealed
that  the  normal  TACSTD2  protein  distributes  both  at  the
plasma membrane and in the cytoplasm while the mutated
TACSTD2 protein was found to be diffusely distributed in the
cytoplasm with no apparent plasma membrane localization
(Figure  3).  Detergent  treatment  with  0.1%  Tween-20
significantly  increased  the  number  of  V5-immunopositive
cells  among  the  cells  transfected  with  the  mutated
TACSTD2 gene, confirming the cytoplasmic localization of
the mutated TACSTD2 protein.
DISCUSSION
In  this  study,  we  have  identified  two  novel  homozygous
mutations from 3 unrelated GDLD patients with a phenotype
well co-segregated with the genotype within their respective
families.  The  insertional  mutation  of  TACSTD2  that  was
found in 2 of the GDLD patients may have resulted from a
flame-shift amino acid alteration with premature termination
(p.Ile281SerfsX23)  within  the  transmembrane  domain.  A
substitutive mutation found in 1 of the GDLD patients may
have resulted from a nonsense mutation (p.Tyr225X) within
a region between the thyroglobulin type-1 and transmembrane
domains.  The  transmembrane  domain  should  support  the
hydrophobic  scaffold  which  may  be  fundamental  to  the
membrane binding property of this protein. However, and as
far  as  we  know,  such  a  domain  structure  is  only  a
computationally speculated model from the primary amino
acid  structure  of  this  protein.  Therefore,  the  subcellular
localization of both the wild-type and mutated TACSTD2
proteins was experimentally determined in this study.
Other than the changes in the subcellular localization of
the TACSTD2 protein in the GDLD patients as identified in
this current study, the functions of the TACSTD2 protein have
yet to be elucidated. Using electron microscopy, Kinoshita et
al.  [19]  demonstrated  an  enlarged  intercellular  space  and
facilitated scaling of the superficial cells of corneal epithelium
in GDLD corneas. Quantock et al. [20] reported the increased
permeability in the epithelium of the GDLD cornea using
horseradish peroxidase as a molecular tracer. Takaoka et al.
[21] found decreased expression of the tight junction–related
protein including claudins (CLDNs), zonula occludens-1, and
occludin in GDLD corneas. Recently, we discovered that the
TACSTD2 protein directly binds to CLDN1 and 7 proteins
and protects them from degradation by ubiquitin-proteasome
system [22]. In the absence of functional TACSTD2 protein,
the CLDN proteins will be degraded and tight junctions will
not be formed, resulting in the hyperpermeation of tear fluid
into  the  cornea,  ultimately  leading  to  the  subepithelial
deposition of amyloid in the cornea.
It  has  been  reported  that  an  AxxxG  motif  in  the
transmembrane  domain  of  the  epithelial  cell  adhesion
molecule  (EpCAM)  protein,  a  paralogous  gene  of  the
TACSTD2 gene, is involved in the binding of the EpCAM
protein to the CLDN7 protein [23]. Since the transmembrane
domain of the TACSTD2 protein also has the AxxxG motif at
the corresponding site to the EpCAM protein [22], only the
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967membrane-bound  TACSTD2  protein  seems  to  have  the
potential to execute the binding activity to CLDNs. Thus, we
strongly believe that the mutated TACSTD2 protein being
devoid of the binding property to the plasma membrane is
actually pathological, as is shown in the present study.
Interestingly, the 20-base insertion mutation was found
in 2 unrelated GDLD patients. Considering the fact that this
mutation has thus-far not been reported, along with the fact
that insertion mutations tend to be much rarer compared to
substitution mutations, this mutation seems to be a founder
mutation caused in a single Japanese ancestor, as has been
reported in GDLD [6] and TGFBI-related corneal dystrophies
[24-26]. Therefore, although these 2 GDLD patients are not
related to one-another, they may have a common ancestor who
may bear one de novo mutation of TACSTD2, possibly at one
of his or her alleles.
In  summary,  we  report  here  two  novel  mutations  of
TACSTD2 and their altered subcellular localization in the
Figure 2. Results of sequencing analysis, PCR
analysis,  and  single-base  primer  extension
assay. A: Nucleotide and amino acid sequence
of TACSTD2. Arrowheads indicate the site of
the  c.675C>A  and  c.
840_841insTCATCATCGCCGGCCTCATC
nucleotide changes. Note that the amino acids
in bold italic type are of the transmembrane
domain.  B:  Computationally-predicted
domain  structure  of  the  TACSTD2  protein
with mutations of previous reports and this
report (*). SS: signal sequence; EGF: EGF-
like repeat; TY: thyroglobulin type I repeat;
TM:  transmembrane  domain;  PIP2:  PIP2
binding sequence. C: Results of sequencing
analysis of TACSTD2 in a normal volunteer
(upper) and in proband A or B (lower). The
underlined nucleotides indicate the inserted
20-base  sequence  between  the  840th  and
841st nucleotide positions of TACSTD2. Note
that the presented sequence is in a reverse
direction. D: Results of sequencing analysis
of TACSTD2 in a normal volunteer (upper)
and  in  proband  C  (lower).  Arrowheads
indicate the site of the c.675C>A mutation.
Note  that  the  presented  sequence  is  in  a
reverse direction. E: Results of PCR analysis
to examine the difference in length between
the normal and insertion-bearing alleles in the
families of the proband A (left) and proband
B (right). The upper bands indicate the PCR
product  derived  from  the  insertion-bearing
alleles while the lower bands indicate the PCR
product from the normal alleles. Note that the
sister  of  proband A  was  not  examined.  F:
Results of 1-base primer extension analysis
for the 675th nucleotide of TACSTD2 in the
normal  volunteer  (left)  and  the  proband  C
(right). Black indicates C and green indicates
A. Note that the presented data was produced
by the forward primer.
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968corneal epithelial cells in vitro. The TACSTD2 protein may
have various unidentified functions other than those that we
have already shown, and we hope that the findings presented
in  this  study  will  provide  the  next  step  toward  a  better
understanding of the pathogenesis of GDLD.
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